RetaCalc
Protocol library
SingleApprovedRegulatory LabelHigh confidenceSourced

Oxytocin

An authorised peptide hormone for specific obstetric indications. Labelled intravenous and intramuscular use requires professional monitoring and is not a wellness protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Regulatory LabelIntravenous infusionContinuous monitored infusion
Labelled induction or stimulation of labour

Monitored intravenous infusion starts at no more than 1-2 milliunits/minute and may increase by no more than 1-2 milliunits/minute to uterine response

The label requires an infusion pump plus frequent uterine and fetal-heart monitoring, with immediate discontinuation for uterine hyperactivity or fetal distress.

View source
Regulatory LabelIV infusion or IMObstetric use
Labelled control of postpartum uterine bleeding

10-40 units may be added to 1,000 mL infusion fluid, or 10 units may be given intramuscularly after delivery of the placenta

These indication-specific professional quantities are not transferable to intranasal, wellness or research-vial use.

View source

Evidence summary

An authorised peptide hormone for specific obstetric indications. Labelled intravenous and intramuscular use requires professional monitoring and is not a wellness protocol.

Protocol basis

The highest-confidence protocol source is authorised obstetric labelling, which specifies professional intravenous infusion or intramuscular use by indication. This site does not reproduce it as a self-use calculator.

What remains uncertain

Intranasal behavioural findings are heterogeneous, and they do not establish broad psychiatric, social or wellness treatment.

Warnings and contraindications

Obstetric oxytocin can cause uterine hyperstimulation, fetal compromise and water intoxication.
Intravenous induction protocols require continuous maternal and fetal monitoring.
Intranasal research and compounded vials are not equivalent to labelled obstetric products.